EPS Bio Technology Corp. (4183) AI Stock Analysis

EPS Bio Technology Corp.

(TPEx:4183)

Select Model

Rating:46Neutral

Price Target:TWD 14.00▼(-3.45% Downside)

Action:initiatedcoverage

Date:11/10/26

Weak profitability and cash generation are the primary risks, outweighing revenue growth and the relatively solid balance sheet. Mildly constructive technical conditions and the dividend yield provide limited support, resulting in a below-average overall score.

Positive Factors

Revenue ReboundThe sharp 2025 revenue rebound indicates that demand or commercial activity recovered meaningfully after the prior period. If sustained, stronger sales can improve operating leverage, support reinvestment, and provide a larger base from which the company can rebuild profitability.

Negative Factors

Profitability DeteriorationThe shift from profit to loss, combined with lower gross margins, weakens confidence in the quality and sustainability of the revenue rebound. Unless pricing, costs, or product mix improve, additional sales may not translate into earnings and could leave returns structurally under pressure.

EPS Bio Technology Corp. (4183) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 342.72M
Dividend Yield: 4.62%
Average Volume (3M): 8,677
Price to Earnings (P/E): -13.9
Beta (1Y): 0.27
Revenue Growth: -23.50%
EPS Growth: -73.10%
Country: TW
Employees: 108
Sector: General
Sector Strength: 55
Industry: Medical - Specialties

EPS Bio Technology Corp. Business Overview & Revenue Model

Company Description

EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity...

EPS Bio Technology Corp. Financial Statement Overview

Summary

Revenue grew 10.8%, but profitability and cash generation weakened substantially. The balance sheet is relatively solid, while negative earnings, very low operating cash flow, and negative free cash flow materially reduce the score.

Income Statement

42Neutral

Balance Sheet

66Positive

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	418.74M	499.70M	451.08M	470.17M	463.45M	480.28M
Gross Profit	63.76M	81.93M	96.27M	115.71M	107.42M	120.67M
EBITDA	2.06M	6.29M	34.46M	44.09M	49.50M	45.49M
Net Income	-9.85M	-7.87M	17.31M	20.99M	25.36M	18.64M
Balance Sheet
Total Assets	503.19M	533.25M	541.89M	543.16M	527.76M	577.45M
Cash, Cash Equivalents and Short-Term Investments	131.56M	123.08M	128.94M	195.29M	178.66M	203.42M
Total Debt	137.90M	140.75M	110.14M	115.81M	121.40M	126.47M
Total Liabilities	235.84M	252.14M	237.34M	237.13M	219.41M	278.18M
Stockholders Equity	267.35M	281.11M	304.55M	306.04M	308.36M	299.27M
Cash Flow
Free Cash Flow	-8.29M	-21.76M	-46.75M	45.69M	-9.96M	19.95M
Operating Cash Flow	9.72M	603.00K	-32.34M	55.17M	5.00M	32.08M
Investing Cash Flow	-20.79M	-23.97M	-14.40M	-9.48M	-14.92M	-12.14M
Financing Cash Flow	18.38M	18.00M	-24.72M	-28.91M	-22.59M	-34.02M

EPS Bio Technology Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4183 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4183	46Neutral	TWD 345.10M	-13.92	―	4.62%	-23.50%	-73.10%
TW:6661	44Neutral	TWD 372.87M	-234.26	―	―	15.25%	-171.60%

* General Sector Average

Performance Comparison

TW:4183 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4183	EPS Bio Technology Corp.	14.50	-3.50	-19.44%
TW:4117	General Biologicals Corp.	7.41	-4.79	-39.26%
TW:6661	Welgene Biotech Co., Ltd.	16.00	-2.60	-13.98%
TW:6734	iXensor Co., Ltd.	5.30	-1.40	-20.91%
TW:6848	RBC Bioscience Corporation	20.95	6.66	46.66%
TW:7595	Pharmigene, Inc.	8.20	-3.00	-26.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

EPS Bio Technology Corp. AI Stock Analysis